Literature DB >> 19022862

Genotype-Phenotype correlations in multiple sclerosis: HLA genes influence disease severity inferred by 1HMR spectroscopy and MRI measures.

D T Okuda1, R Srinivasan, J R Oksenberg, D S Goodin, S E Baranzini, A Beheshtian, E Waubant, S S Zamvil, D Leppert, P Qualley, R Lincoln, R Gomez, S Caillier, M George, J Wang, S J Nelson, B A C Cree, S L Hauser, D Pelletier.   

Abstract

Genetic susceptibility to multiple sclerosis (MS) is associated with the human leukocyte antigen (HLA) DRB1*1501 allele. Here we show a clear association between DRB1*1501 carrier status and four domains of disease severity in an investigation of genotype-phenotype associations in 505 robust, clinically well characterized MS patients evaluated cross-sectionally: (i) a reduction in the N-acetyl-aspartate (NAA) concentration within normal appearing white matter (NAWM) via (1)HMR spectroscopy (P = 0.025), (ii) an increase in the volume of white matter (WM) lesions utilizing conventional anatomical MRI techniques (1,127 mm(3); P = 0.031), (iii) a reduction in normalized brain parenchymal volume (nBPV) (P = 0.023), and (iv) impairments in cognitive function as measured by the Paced Auditory Serial Addition Test (PASAT-3) performance (Mean Z Score: DRB1*1501+: 0.110 versus DRB1*1501-: 0.048; P = 0.004). In addition, DRB1*1501+ patients had significantly more women (74% versus 63%; P = 0.009) and a younger mean age at disease onset (32.4 years versus 34.3 years; P = 0.025). Our findings suggest that DRB1*1501 increases disease severity in MS by facilitating the development of more T2-foci, thereby increasing the potential for irreversible axonal compromise and subsequent neuronal degeneration, as suggested by the reduction of NAA concentrations in NAWM, ultimately leading to a decline in brain volume. These structural aberrations may explain the significant differences in cognitive performance observed between DRB1*1501 groups. The overall goal of a deep phenotypic approach to MS is to develop an array of meaningful biomarkers to monitor the course of the disease, predict future disease behaviour, determine when treatment is necessary, and perhaps to more effectively recommend an available therapeutic intervention.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19022862      PMCID: PMC2638695          DOI: 10.1093/brain/awn301

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  52 in total

1.  Segmentation of brain MR images through a hidden Markov random field model and the expectation-maximization algorithm.

Authors:  Y Zhang; M Brady; S Smith
Journal:  IEEE Trans Med Imaging       Date:  2001-01       Impact factor: 10.048

Review 2.  Identifying disease modifying genes in multiple sclerosis.

Authors:  Orhun H Kantarci; Mariza de Andrade; Brian G Weinshenker
Journal:  J Neuroimmunol       Date:  2002-02       Impact factor: 3.478

3.  Normalized accurate measurement of longitudinal brain change.

Authors:  S M Smith; N De Stefano; M Jenkinson; P M Matthews
Journal:  J Comput Assist Tomogr       Date:  2001 May-Jun       Impact factor: 1.826

4.  Genetic factors and the founder effect explain familial MS in Sardinia.

Authors:  M G Marrosu; M Lai; E Cocco; V Loi; G Spinicci; M P Pischedda; S Massole; G Marrosu; P Contu
Journal:  Neurology       Date:  2002-01-22       Impact factor: 9.910

5.  Interaction between HLA-DR2 and abnormal brain MRI in optic neuritis and early MS. Optic Neuritis Study Group.

Authors:  S L Hauser; J R Oksenberg; R Lincoln; J Garovoy; R W Beck; S R Cole; P S Moke; K E Kip; R L Gal; D T Long
Journal:  Neurology       Date:  2000-05-09       Impact factor: 9.910

6.  HLA-DRB1*1501 and response to copolymer-1 therapy in relapsing-remitting multiple sclerosis.

Authors:  C Fusco; V Andreone; G Coppola; V Luongo; F Guerini; E Pace; C Florio; G Pirozzi; R Lanzillo; P Ferrante; P Vivo; M Mini; M Macrì; G Orefice; M L Lombardi
Journal:  Neurology       Date:  2001-12-11       Impact factor: 9.910

7.  Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction.

Authors:  S M Rao; G J Leo; L Bernardin; F Unverzagt
Journal:  Neurology       Date:  1991-05       Impact factor: 9.910

8.  Genetic basis for clinical expression in multiple sclerosis.

Authors:  L F Barcellos; J R Oksenberg; A J Green; P Bucher; J B Rimmler; S Schmidt; M E Garcia; R R Lincoln; M A Pericak-Vance; J L Haines; S L Hauser
Journal:  Brain       Date:  2002-01       Impact factor: 13.501

Review 9.  Genetic factors in multiple sclerosis.

Authors:  J R Oksenberg; A B Begovich; H A Erlich; L Steinman
Journal:  JAMA       Date:  1993-11-17       Impact factor: 56.272

10.  Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis.

Authors:  W I McDonald; A Compston; G Edan; D Goodkin; H P Hartung; F D Lublin; H F McFarland; D W Paty; C H Polman; S C Reingold; M Sandberg-Wollheim; W Sibley; A Thompson; S van den Noort; B Y Weinshenker; J S Wolinsky
Journal:  Ann Neurol       Date:  2001-07       Impact factor: 10.422

View more
  45 in total

Review 1.  Multiple sclerosis genetics--is the glass half full, or half empty?

Authors:  Jorge R Oksenberg; Sergio E Baranzini
Journal:  Nat Rev Neurol       Date:  2010-07-13       Impact factor: 42.937

Review 2.  The genetics of multiple sclerosis: an up-to-date review.

Authors:  Pierre-Antoine Gourraud; Hanne F Harbo; Stephen L Hauser; Sergio E Baranzini
Journal:  Immunol Rev       Date:  2012-07       Impact factor: 12.988

3.  Identifying patient subtypes in multiple sclerosis and tailoring immunotherapy: challenges for the future.

Authors:  Philip L De Jager
Journal:  Ther Adv Neurol Disord       Date:  2009-11       Impact factor: 6.570

Review 4.  Genetic determinants of risk and progression in multiple sclerosis.

Authors:  Alessandro Didonna; Jorge R Oksenberg
Journal:  Clin Chim Acta       Date:  2015-02-04       Impact factor: 3.786

5.  Predictive factors of neutralizing antibodies development in relapsing-remitting multiple sclerosis patients on interferon Beta-1b therapy.

Authors:  R Lanzillo; G Orefice; A Prinster; G Ventrella; R Liuzzi; V Scarano; C Florio; G Vacca; A Brunetti; B Alfano; V Brescia Morra; V Bonavita
Journal:  Neurol Sci       Date:  2011-02-10       Impact factor: 3.307

6.  Association of HLA Genetic Risk Burden With Disease Phenotypes in Multiple Sclerosis.

Authors:  Noriko Isobe; Anisha Keshavan; Pierre-Antoine Gourraud; Alyssa H Zhu; Esha Datta; Regina Schlaeger; Stacy J Caillier; Adam Santaniello; Antoine Lizée; Daniel S Himmelstein; Sergio E Baranzini; Jill Hollenbach; Bruce A C Cree; Stephen L Hauser; Jorge R Oksenberg; Roland G Henry
Journal:  JAMA Neurol       Date:  2016-07-01       Impact factor: 18.302

7.  Linking Genotype to Clinical Phenotype in Multiple Sclerosis: In Search of the Holy Grail.

Authors:  Erin E Longbrake; David A Hafler
Journal:  JAMA Neurol       Date:  2016-07-01       Impact factor: 18.302

8.  In vivo evidence of glutamate toxicity in multiple sclerosis.

Authors:  Christina J Azevedo; John Kornak; Philip Chu; Mehul Sampat; Darin T Okuda; Bruce A Cree; Sarah J Nelson; Stephen L Hauser; Daniel Pelletier
Journal:  Ann Neurol       Date:  2014-07-09       Impact factor: 10.422

9.  Genetic associations with brain cortical thickness in multiple sclerosis.

Authors:  T Matsushita; L Madireddy; T Sprenger; P Khankhanian; S Magon; Y Naegelin; E Caverzasi; R L P Lindberg; L Kappos; S L Hauser; J R Oksenberg; R Henry; D Pelletier; S E Baranzini
Journal:  Genes Brain Behav       Date:  2015-03-05       Impact factor: 3.449

10.  Multiple sclerosis susceptibility-associated SNPs do not influence disease severity measures in a cohort of Australian MS patients.

Authors:  Cathy J Jensen; Jim Stankovich; Anneke Van der Walt; Melanie Bahlo; Bruce V Taylor; Ingrid A F van der Mei; Simon J Foote; Trevor J Kilpatrick; Laura J Johnson; Ella Wilkins; Judith Field; Patrick Danoy; Matthew A Brown; Justin P Rubio; Helmut Butzkueven
Journal:  PLoS One       Date:  2010-04-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.